1 UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results 2 from the randomized phase 2 FOCUS trial 3

4

5 Anna Brandt¹, Konrad Klinghammer², Christoph Schultheiss^{1,3}, Lisa Paschold⁴, Claudia Wickenhauser⁵, Marcus Bauer⁵, Anna Bergqvist⁶, Dennis Hahn⁷, Philippe 6 Schafhausen⁸, Mareike Tometten⁹, Markus Blaurock¹⁰, Henrike Barbara Zech¹¹, Chia-7 Jung Busch¹⁰, Andreas Dietz¹², Urs Müller-Richter¹³, Jürgen Alt¹⁴, Andreas Boehm¹⁵, 8

Simone Kowoll¹⁶, Jörg Steighardt¹⁶, Alexander Lasch¹⁶, Ingunn Hagen Westgaard⁶. 9

Marita Westhrin⁶, Alexander Stein¹⁷, Axel Hinke¹⁸, Mascha Binder^{1,3} 10

11

Affiliations 12

- ¹ Division of Medical Oncology, University Hospital Basel, Basel, Switzerland 13
- ² Department of Hematology and Oncology, Campus Benjamin Franklin, Charité -14
- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-15
- Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany 16
- ³ Laboratory of Translational Immuno-Oncology, Department of Biomedicine, 17
- 18 University and University Hospital Basel, Basel, Switzerland
- ⁴ Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University 19
- 20 Halle-Wittenberg, Halle (Saale), Germany
- ⁵ Institute of Pathology, University Hospital Halle, Martin-Luther-University Halle-21
- 22 Wittenberg, Halle (Saale), Germany
- ⁶ Ultimovacs ASA, Oslo, Norway 23
- 24 ⁷ Klinikum Stuttgart, Stuttgart, Germany; Dept. of Hematology, Oncology, Stem-Cell
- Transplantation and Palliative Care 25
- ⁸ Department of Oncology, Hematology and Bone Marrow Transplantation with 26
- Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, 27
- Germany 28
- 9 Department of Hematology, Oncology, Hemostaseology and Stem Cell 29 Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany 30
- ¹⁰ Department of Otorhinolaryngology, Head and Neck Surgery, University Medicine 31
- Greifswald, Greifswald, Germany 32
- ¹¹ Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, 33
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Hamburg, Germany 34

35	¹² Department of Otolaryngology, Head and Neck Surgery, University of Leipzig,
36	Leipzig, Germany
37	¹³ University Hospital Würzburg, Bavarian Cancer Research Center (BZKF),
38	Würzburg, Germany
39	¹⁴ Department of Internal Medicine III (Hematology, Oncology), University Medical
40	Center Mainz, Mainz, Germany
41	¹⁵ Department of Otorhinolaryngology, St. Georg Hospital, Leipzig, Germany
42	¹⁶ Coordination Center for Clinical Trials, Medical Faculty, Martin-Luther-University
43	Halle-Wittenberg, Halle (Saale), Germany
44	¹⁷ Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany
45	¹⁸ Clinical Cancer Research Consulting (CCRC), Düsseldorf, Germany
46	
47	Funding: The trial including translational research was funded by a research grant
48	from ULTIMOVACS.
49	
50	Corresponding author: Mascha Binder, Medical Oncology, University Hospital
51	Basel, Switzerland, mascha.binder@usb.de
52	
53	Running title: UV1 vaccination in head and neck cancer
5/	3
54	Keywarday IIV/1, nombrolizymab, bood and nock concer
22	Rey words. OV 1, periorolizumab, nead and neck cancel
56	
57	Conflicts of interest:
58	Mascha Binder received institutional research grants from Merck, BMS, Hexal,
59	Novartis, German Cancer Aid (Krebshilfe), German Research Foundation and the
60	Federal Ministry of Education and Research as well as honoraria for lectures and
61	advisory board meetings by Celgene, Janssen, Gilead, Merck, Roche, Amgen, Sanofi-
62	Aventis and BMS. She received funding for the FOCUS trial from ULTIMOVACS.

Alexander Stein received research funding from MSD and serves as an advisory board 63 member for MSD. Urs Müller-Richter serves as a consultant or advisor and/or received 64 honoraria from AstraZeneca, BioNTech, BMS, KuraOncology, Merck, MSD, Novartis, 65 and Sanofi. Jürgen Alt serves as an advisor for AstraZeneca, MSD, Novartis, Roche, 66 BMS, Janssen, and Merck and received honoraria from AstraZeneca, BMS, Roche, 67 and Boehringer Ingelheim. Konrad Klinghammer serves as a consultant or advisor 68 69 and/or received honoraria from MSD, Merck, BMS, Roche, Novartis, Sanofi, Bayer, BioNTech, Boehringer Ingelheim, and onkowissen. Anna Brandt received honoraria 70 71 from Merck. Dennis Hahn serves as a consultant or advisor and/or received honoraria 72 from BMS, MSD and Merck. Henrike Barbara Zech serves as a consultant and /or received honoraria from MSD, Merck, BMS, Sanofi, Regeneron. Chia-Jung Busch 73 received institutional research grants from BMS and German Cancer Aid (Krebshilfe) 74 as well as honoraria for lectures and advisory board meetings by Bayer, BMS, GSK, 75 Merck, MSD, Sanofi-Aventis. Ingunn Hagen Westgaard, Anna Berggvist and Marita 76 Westhrin are employed by Ultimovacs ASA. Philippe Schafhausen serves as a 77 consultant or advisor and/or received honoraria from Alexion, AOP Orphan 78 Pharmaceutical, Blueprint Medicines, GSK, MSD, Merck, BMS, Novartis, Pfizer, 79 Roche, Sanofi, and Sobi. All other authors declare no potential conflict of interest. 80

81

83 Abstract

<u>Background:</u> Human telomerase reverse transcriptase (hTERT) is highly expressed (75-100%) in head and neck squamous cell carcinoma (HNSCC). The FOCUS study examines the role of the hTERT-directed vaccine UV1 in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.

<u>Methods:</u> The FOCUS trial, a two-armed, open-label, non-comparative, randomized, multicenter phase 2 study, was designed to assess the efficacy and feasibility of UV1 as an add-on to pembrolizumab in the first-line treatment of patients with R/M PD-L1 positive HNSCC. A progression-free survival rate at 6 months (PFSR@6) of 40% was deemed promising for further development in a phase 3 setting. The trial was conducted in 10 centers in Germany.

94 <u>Results</u>: From August 2021 to July 2023, 25 patients were enrolled in the calibration 95 arm A and 50 patients in the UV1 arm B. Median age was 65 years and 18% of patients 96 had an ECOG performance score of 2. The PFSR@6 was 30% in the UV1 arm. No 97 specific safety signals were observed in the UV1 arm apart from a reversible allergic 98 reaction that appeared in one patient. At a median follow-up of almost one year (11.3 99 months), median overall survival was 13.1 months in the calibration arm A and 12.6 100 months in the UV1 arm B. Clinical trial identification number NCT05075122.

<u>Conclusions:</u> The addition of UV1 to pembrolizumab was safe but did not show an
 efficacy signal in this study population.

103

105 Introduction

Head and neck squamous cell carcinoma (HNSCC) ranks as the seventh most prevalent cancer globally and is linked to tobacco use, alcohol consumption, and human papillomavirus (HPV) infection in oropharyngeal cancer (*1, 2*). Initial-stage therapy aims for a cure, yet more than half of HNSCC patients experience recurrent and/or metastatic (R/M) disease despite aggressive multimodal approaches (*3*). Many patients with R/M HNSCC qualify solely for palliative systemic therapy (*4*).

The incorporation of the epidermal growth factor receptor (EGFR) antibody cetuximab 112 into platinum and fluorouracil (EXTREME regimen) substantially increased overall 113 114 survival from 7.4 to 10.1 months as first-line treatment for R/M HNSCC, becoming the standard in 2008 (4, 5). More recently, the FDA approved pembrolizumab, a 115 programmed death 1 (PD-1) immune checkpoint inhibitor, for first-line treatment based 116 on the KEYNOTE-048 trial. Pembrolizumab with chemotherapy demonstrated 117 improved overall survival compared to cetuximab with chemotherapy (median 13.0 vs. 118 10.7 months) (6). Particularly in patients with PD-L1 Combined Positive Score (CPS) 119 \geq 1 and CPS \geq 20, pembrolizumab alone outperformed cetuximab with chemotherapy, 120 underscoring increased efficacy with higher PD-L1 expression (7). 121

Despite durable responses in some patients, the majority (85-95%) of R/M HNSCC 122 patients exhibit either no response or short-term benefit to immune checkpoint 123 inhibitors (3). Insufficient T cell effector response might contribute to this lack of 124 response (8). Efforts to enhance T cell response involve investigating therapeutic 125 cancer vaccines, such as UV1, targeting human telomerase reverse transcriptase 126 (hTERT), a key player in carcinogenesis activated in 85-90% of cancers (8-12). UV1 127 induced persistent immune responses lasting up to 7.5 years in phase I trials in 128 patients with advanced melanoma, non-small cell lung cancer and prostate cancer, 129

- 130 with promising results when combined with checkpoint inhibitors in the melanoma
- 131 patients (8).
- 132 In HNSCC, where high hTERT expression (75-100%) is prevalent (13), the FOCUS
- trial (14) sought to evaluate the effectiveness of UV1 vaccination combined with
- pembrolizumab versus pembrolizumab alone in patients with PD-L1 positive R/M
- 135 HNSCC.

136 **Results**

137 Disposition of study patients

138 Table 1: Patient disposition and categories of evaluability (CONSORT)

Parameter	Arm A	Arm B	Total
Randomised patients	26	52	78
Non-eligible for analysis (major primary protocol violation), randomised	-	2*	2*
No data available, randomised	1**	-	1**
Full analysis population (ITT) for this report***	25	50	75
Evaluability (ITT) with respect to			
Tumor response (iRECIST) at end of protocol treatment	22	45	67***
Progression-free survival (PFS)	25	50	75
PFS rate at 6 months (primary endpoint)	25	50	75
Overall survival (OS)	25	50	75
Evaluability for safety	25	50	75

139

* Two patients were excluded due to severe violation of entry criteria, present at randomization:
 performance status too poor (ECOG >2) and required antibiotic treatment; no protocol therapy applied.
 ** Informed consent withdrawn one day after randomization; no protocol therapy applied. *** With a
 valid iRECIST re-staging.

144 145

Recruitment started in August 2021 and was closed in July 2023. Data base lock was July 24th, 2024. A total of 78 patients from a total of ten different study sites were randomized (Table 1). At its final closure, the database included information on 75 randomized, evaluable patients, 25 in arm A (calibration arm, pembrolizumab alone) and 50 in arm B (experimental arm, pembrolizumab and UV1 vaccination), forming the ITT full analysis set (Table 1). One patient did not receive the first protocol-defined pembrolizumab cycle and was excluded from the per-protocol (PP) population.

155 Baseline characteristics

156 Table 2: Baseline characteristics of eligible patients

Parameter	Arm A	Arm B	Total
n	25	50	75
Age			
Mean ± SD	64.5 ± 11.3	67.5 ± 10.5	66.5 ± 10.8
Sex			
Female	7 (28%)	8 (16%)	15 (20%)
Male	18 (72%)	42 (84%)	60 (80%)
ECOG			
n	24	48	72*
ECOG 0	8 (33%)	17 (35%)	25 (35%)
ECOG 1	9 (38%)	24 (50%)	33 (46%)
ECOG 2	7 (29%)	6 (12%)	13 (18%)
ECOG 3	0 (0%)	1 (2%)**	1 (1%)**

 ^{*} The baseline vital sign visit was missing in 3 patients. ** Patient needing a wheelchair due to a non oncological condition; accepted for inclusion by principal investigator; ECOG, Eastern Cooperative
 Oncology Group; n, number

160

Age and gender were equally distributed among the study arms, with a slight tendency
to more elderly and male patients in the experimental arm (Table 2). In contrast, there
was a slight trend towards less favourable ECOG performance status in arm A (Table
2).

- 166 Disease status at recruitment
- 167 Overall, clinical features were relatively well balanced between the arms. Most patients
- (fewer in arm B) entered the FOCUS trial due to relapsing disease (Table 3). While
- advanced stages of the primary tumor were slightly more frequent in the UV1 arm B,
- more patients with distant metastases were randomised to arm A (Table 3). Distant

- metastases were predominantly located in the lung (Table 3). Median PD-L1 CPS was 171
- 35 (range 1-100) in arm A and 27 (range 1-100) in the UV1 arm B. 172
- 173

Table 3: Disease status at recruitment 174

Parameter	Arm A	Arm B	Total	
Disease status				
n	25	50	75	
Relapse	21 (84%)	34 (68%)	55 (73%)	
Initial diagnosis	4 (16%)	16 (32%)	20 (27%)	
Stage	1			
n	25	47	72	
Stage I	-	1 (2%)	1 (1%)	
Stage II	-	5 (11%)	5 (7%)	
Stage III	1 (4%)	4 (9%)	5 (7%)	
Stage IVa	6 (24%)	12 (26%)	18 (25%)	
Stage IVb	6 (24%)	9 (19%)	15 (21%)	
Stage IVc	12 (48%)	16 (34%)	28 (39%)	
Location of metastases	I	L		
n	15	22	37	
Bone	1 (7%)	2 (9%)	3 (8%)	
Liver	4 (27%)	3 (14%)	7 (19%)	
Lung	8 (53%)	12 (55%)	20 (54%)	
Skin	2 (13%)	1 (5%)	3 (8%)	
Other	4 (27%)	6 (27%)	10 (27%)	
Pre-treatment				
n	25	50	75	
Surgery	13 (52%)	29 (58%)	42 (56%)	
Adjuvant radiotherapy	3 (12%)	7 (14%)	10 (13%)	
Adjuvant chemoradiotherapy	8 (32%)	20 (40%)	28 (37%)	

All rights reserved.	No reuse allowed without	permission.
J		

Definitive chemoradiotherapy	3 (12%)	8 (16%)	11 (15%)
Radiotherapy	5 (20%)	7 (14%)	12 (16%)
Other	2 (8%)	3 (6%)	5 (7%)

175

176 Antineoplastic treatment and duration of follow-up

177 Median duration of pembrolizumab treatment was 15.1 weeks (range 0.1-98.6) in arm

A versus 12.1 weeks (range 0-84.3) in arm B. Median number of UV1 administrations

per patient was 8 (range 1-8). About half of the patients (54%) received the maximum

180 number of vaccine administrations.

181 Mean duration of follow-up since randomization was slightly shorter than one year

182 (11.3 months), ranging up to 28.7 months, and was quite similar in both study arms

183 (11.7 months in arm A and 11.1 months in arm B).

184

185 Tumor response

Category	Arm A	Arm B	Total
n	22	45	67
CR	3 (14%)	2 (4%)	5 (7%)
PR	7 (32%)	8 (18%)	15 (22%)
SD	1 (5%)	6 (13%)	7 (10%)
PD unconfirmed	4 (18%)	12 (27%)	16 (24%)
PD confirmed	7 (32%)	17 (38%)	24 (36%)

186 Table 4: Response at the end of protocol therapy

187

188 Tumor response according to iRECIST as investigated at the end of protocol therapy,

is shown in Table 4. A total of 67 out of 75 patients had a valid restaging result at this

time point. The corresponding overall response rate (CR + PR = ORR) was 45% in

arm A (95% CI, 24%-68%) and 22% in arm B (95% CI, 11%-37%) (p = 0.086).

192 Progression-free survival

The results for the primary endpoint of the study, i.e. the crude proportion of patients 193 surviving without progression at 6 months after randomization, are shown in Table 5. 194 With respect to the formal study hypothesis, the two-sided 80% CI (corresponding to 195 the 90% one-sided CI as relevant for superiority) of the rate in the experimental arm B 196 does not exclude the 25% boundary, which was pre-defined as futility threshold. 197 198 Moreover, the 40% finding in the group treated with pembrolizumab alone (arm A) is higher than expected. Thus, a positive signal for the experimental treatment cannot be 199 200 derived from the results of this phase 2 study.

201

202 Table 5: Crude PFS rate at 6 months (primary endpoint)

Parameter	Arm A	Arm B
n	25	50
Number of patients surviving free from progression at 6 months	10	15
Crude rate	40%	30%
Exact 95% Cl	21%-61%	18%-45%
Exact 90% Cl	24%-58%	19%-42%
Exact 80% CI	27%-55%	21%-40%

203

Correspondingly, the Kaplan-Meier estimation of progression-free survival (PFS) from the time point of randomization (Figure 1A), based on a total of 63 observed PFS events in the ITT population of 75 patients (84%), shows no major difference between the arms. The medians in arm A and B are similar with 3.9 (95% CI, 3.0-13.1) and 3.3 months (95% CI, 3.2-4.4), respectively. The 6-month PFS rates estimated according to Kaplan-Meier are 42% (95% CI, 26%-67%) and 31% (95% CI, 20%-47%),

respectively. The hazard ratio (HR) amounts to 1.3 (95% CI, 0.76-2.23) suggesting no
relevant difference between the arms.

The Kaplan-Meier estimation of overall survival (OS) from the time point of randomization, based on a total of 46 observed deaths in the ITT population of 75 patients (61%) is provided in Figure 1B. The medians in arm A and B were similar with 13.1 (95% CI, 7.7-undefined) and 12.6 months (95% CI, 9.5-19.6), respectively. The hazard ratio amounts to 1.22 (95% CI: 0.64-2.32).



217

Figure 1. Efficacy of UV1 + pembrolizumab treatment in patients with R/M HNSCC. A, Kaplan Meier estimates of progression-free survival. B, Kaplan-Meier estimates of overall survival.

221 Safety

The safety analysis is based on the total population of 75 patients. A total of 61 grade 3 or higher adverse events (AEs) were recorded in the ITT population, 44% of patients in arm A and 50% in arm B experienced at least one such AE. Table 6 presents an overview of observed adverse events, overall and according to severity and other predefined categories. No relevant differences between the two study arms were detected.

228

230 Table 6: Overview of adverse events

Parameter	Arm A	Arm B
n	25	50
Total number of adverse events reported	124	263
Number of adverse events of severity grade 3 to 5	21	40
Number of patients with any adverse event	25 (100%)	47 (94%)
Number of patients with any adverse event of severity grade 3 to 5	11 (44%)	25 (50%)
Number of patients with any serious AE (SAE)	10 (40%)	28 (56%)
Number of patients with any AE of special interest	NA	1 (2%)*

231 *Severe anaphylactic reaction

232

Grade 3 or higher AEs are summarized in Table 7.

234 Table 7. Patients experiencing grade 3 or higher adverse events

Adverse event	Arm A n=25	Arm B n=50
Infection	5 (20%)	7 (14%)
Sepsis	1 (4%)	0
Lipase increased	0	1 (2%)
Abdominal pain	0	1 (2%)
Diarrhea	0	1 (2%)*
Allergic reaction	0	1 (2%)

^{235 *}Grade missing

- 237 hTERT tissue expression
- hter tissue expression at baseline was assessed in 63 patients. There was a trend
- to longer progression free survival with hTERT expression >0 in arm B, however, this
- trend was also seen in the control arm A (Figure 2).



241

Figure 2. Kaplan-Meier estimates of progression-free survival of patients with hTERT expression >0 242 243 and 0 in arm A (\mathbf{A}) , and arm B (\mathbf{B}) . 244

Immune response to UV1 245

246 To assess UV1-specific T cell responses over time, IFN-y secretion was quantified via ELISPOT assays after stimulation of patient-derived peripheral blood mononuclear 247 cells (PBMCs) obtained at visit 1 (baseline, BL) and follow-up (FU) timepoints (visit 6 248 and/or end of treatment (EOT)/progressive disease (PD)) with UV1 vaccine peptides 249 (p719-20, p728, p725 or the UV1 peptide pool). As shown in Figure 3, individual 250 patients in both study arms displayed UV1-directed T cell responses at baseline. 251 Notably, UV1-directed T cell responses were almost undetectable in the FU time 252 points in arm A without vaccination (Figure 3). UV1-directed T cell responses were 253 observed in 12 of 14 vaccinated individuals (Figure 3, arm B). The highest reactivity 254 was detected after stimulation with the UV1 peptide pool or the p719-20 peptide, while 255 reactivity to the single hTERT peptides p728 and p725 was substantially lower (Figure 256 3). 257

All rights reserved. No reuse allowed without permission.



²⁶⁰

261 Figure 3: Quantification of pre- and post-vaccination immune responses to UV1. UV1-directed T 262 cell responses were quantified using IFN-y ELISPOT after peptide stimulation of patient derived PBMCs. Mean ELISPOT counts per patient are shown for both arms. Sample numbers in arm A: BL 263 n=4, FU n=5; arm B: BL n=16, FU n=13. BL sampled at visit 1, FU sampled at visit 6 and/or end of 264 treatment (EOT)/progressive disease (PD). UV1 refers to hTERT peptide mix (=UV1 vaccine) 265 encompassing the peptides p719-20 (hTERT amino acids 660-689, peptide 728 (hTERT amino acids 266 651-665) and peptide 725 (hTERT amino acids 691-705). 267

268

Discussion 269

The treatment of advanced or recurrent head and neck cancer remains a significant 270 challenge. Current treatment options, such as chemotherapy and immunotherapy are 271 established treatment options albeit with limited efficacy (5, 6, 15). Moreover, most 272 pivotal trials excluded more frail patients who are likely to experience severe side 273 effects and have poorer overall outcomes (16). Therefore, trial results are often not 274 representative for patients with head and neck cancer many of which suffering from 275 concomitant medical conditions (17). Safe and at the same time effective treatment 276 options that spare toxicities in these frail patients would represent a significant 277 278 advancement.

To address these unmet needs, we conducted a phase 2 trial evaluating the hTERT vaccine UV1 in combination with pembrolizumab in a cohort of patients with advanced head and neck cancer. We enrolled patients up to an ECOG performance status of 2. Unfortunately, our findings indicate that the hTERT vaccine UV1 did not demonstrate a signal of efficacy in this population.

Our results stand in contrast to those of previous studies using the same vaccine in other cancers, such as melanoma, where more consistent immune responses were observed (8). In the recently published NIPU-trial a positive overall survival signal was observed in mesothelioma patients when UV1 was combined with ipilimumab and nivolumab (*18*). This discrepancy suggests that the immune environment and tumor biology of head and neck cancers may differ significantly from other tumor types, thereby influencing the efficacy of immunotherapeutic approaches such as UV1.

Despite these disappointing results, our study provides valuable insights into the 291 efficacy of pembrolizumab in a more real-world patient population. In contrast to the 292 293 KEYNOTE-048 trial, which limited the inclusion criteria to an ECOG of 1 due to the possible administration of additional chemotherapy, the FOCUS trial enrolled patients 294 with an ECOG up to 2, made possible by exclusive use of pembrolizumab (6). In this 295 frailer patient population overall response rate, progression-free survival and overall 296 survival with pembrolizumab were comparable to the outcomes of PD-L1 positive 297 patients in the KEYNOTE-048 trial (19). Recently, the results of the randomized phase 298 3 trial ELAN UNFIT have been published, which compared the efficacy and safety of 299 cetuximab to methotrexate in older, frail patients with R/M HNSCC (16). Even though 300 this trial did not show an improvement in failure-free survival with cetuximab versus 301 methotrexate, more trials such as ELAN UNFIT or FOCUS are needed to better 302

understand the unique therapeutic challenges and needs of older patients with headand neck cancer (*20*).

Moreover, our study contributes to the debate about the limitations of current 305 immunotherapy approaches in advanced head and neck cancers. The lack of efficacy 306 observed with the hTERT vaccine UV1 raises important questions about the role of 307 telomerase-targeted immunotherapy in this setting and emphasizes the need for 308 continued exploration of alternative strategies. Our results suggest that while 309 telomerase-targeted immunotherapy holds promise for certain cancers, its application 310 in head and neck cancers does not seem to be promising or would need other 311 therapeutic modalities to enhance efficacy. 312

313

314 Methods

315 <u>Clinical trial</u>

Main inclusion criteria consisted of: Patients had to be at least 18 years of age. ECOG-316 performance score 0-2, with histologically confirmed diagnosis of non-resectable 317 recurrent or metastatic head and neck squamous cell carcinoma with at least one 318 measurable tumor lesion as per RECIST v.1.1. Patients had to be eligible for 319 pembrolizumab monotherapy with a PD-L1 CPS ≥1 and adequate laboratory 320 parameters. The trial was conducted at 10 centers in Germany in compliance with the 321 Declaration of Helsinki. The study protocol was approved by the local ethics 322 committees and authorized by the competent authority. All participants provided 323 written informed consent. The trial is registered with ClinicalTrials.gov 324 (NCT05075122). 325

Eligible patients were randomized to pembrolizumab mono (arm A) or pembrolizumab in combination with UV1 vaccination (arm B). Randomization was done via an online

tool (secuTrial®) of the Coordination Center for Clinical Trials, Medical Faculty, Martin-328 Luther-University Halle-Wittenberg, Halle (Saale), Germany. All patients received 329 pembrolizumab until disease progression or up to two years. In Arm A patients 330 received pembrolizumab 200 mg i.v. every 3 weeks, administration of pembrolizumab 331 started in week 1 (treatment duration of 12 weeks). In arm B patients received 332 pembrolizumab 200 mg i.v. every 3 weeks in combination with UV1 vaccination (300 333 334 µg UV1 s.c. in addition to 75 µg GM-CSF s.c.). Three UV1 doses were applied during week 1, followed by 5 vaccinations every 3 weeks on day 1 of each cycle. In arm B 335 336 administration of pembrolizumab started at week 2, one week later than in arm A (treatment duration of 13 weeks). 337

Radiological baseline assessment by computed tomography of the neck, chest, abdomen and pelvis not older than 4 weeks before randomization was performed. Patients were assessed on week 1, day 1 (visit 1), week 1, day 3 (visit 2), week 1, day 5 (visit 3), week 2 (visit 4), week 5 (visit 5) week 8 (visit 6), week 11 (visit 7), week 14 (visit 8), at the end of treatment (EOT), and at progressive disease (PD) if applicable. All patients were evaluated every 3 months after EOT until death or maximal 12 months after last patient first visit.

The legal funder (sponsor) of the trial was the University Medical Center Halle (Saale),Germany.

347

348 Statistical analysis

The primary endpoint was PFSR@6, defined as the proportion of patients alive without progression at six months after randomization divided by the total number of evaluable patients, and the low boundary of its one-sided 90% confidence interval, corresponding to a type I error level of 0.1. To detect a promising efficacy level of

PFSR@6 \geq 40% against a futility level of \leq 25%, as expected for pembrolizumab singleagent treatment, with a power of 80%, 46 evaluable patients were required in the experimental arm (*21*). By 2:1 ratio, patients were allocated to a randomized reference arm, to allow some control of selection bias.

Due to the lack of adequate power, statistical comparisons between the study arms must be considered exploratory, with all p values being two-sided. Fisher's exact test was applied for nominal data, Student's t test for continuously distributed data, and the log rank test for time-to-event analysis, with hazard ratios derived from Cox models.

361

362 Immunohistochemistry (IHC) for TERT

IHC staining was performed on a Bond III automated immunostainer (Leica
Biosystems Nussloch GmbH, Wetzlar, Germany) using the Bond Polymer Refine
Detection Kit (DS9800-CN). The polyclonal anti-TERT antibody (Telomerase catalytic
subunit Antibody, 600-401-252, Rockland Immunochemicals Inc., Limerick, PA, USA)
was applied in a dilution of 1:500. The staining intensity was scored using the H-score
as described elsewhere (*22*).

369

370 Quantification of anti-hTERT immune responses

PBMCs were seeded in 48-well plates at 6 million cells per well in IMDM medium 371 (Gibco) supplemented with 10% heat-inactivated human 372 serum, penicillin/streptomycin and 50 µM beta-mercaptoethanol. The PBMCs were stimulated 373 with UV1 drug product (peptide 725; hTERT 691-705 (RTFVLRVRAQDPPPE), 374 peptide 719-20; hTERT 660-689 (ALFSVLNYERARRPGLLGASVLGLDDIHRA), 375 peptide 728; hTERT 651-665 (AERLTSRVKALFSVL) (Corden Pharma, Caponago, 376 Italy) at a concentration of 15 µM each and 20 µg/ml poly-ICLC (Oncovir). Medium 377

containing 20 U/ml IL-2 was replaced every two days. For IFN-y ELISPOT assays, 378 cells were harvested on day 12, seeded as triplicates at 0.1 million each in ELISPOT 379 plates (Human IFN-y ImmunoSpot, CTL). The UV1 peptides were added at 20 µM 380 each or 20 µM UV1 peptide mix (= UV1 cancer vaccine). T cells alone served as 381 negative control, T cells stimulated with 0.08µg/ml SEC-3 superantigen (Toxin 382 Technology Inc. Sarasota, FL, USA) as positive control. Cells were incubated for 22 383 hours before enumeration of the detected spots using an automated analyzer, CTL 384 IMMUNOSPOT S5 VERSA-02-9030 (Cellular Technology Ltd, Shaker Heights, OH, 385 386 USA). Specific spots were calculated by subtracting the mean number of spots detected in the medium-only control from the mean number of spots detected in the 387 experimental samples. 388

389 **Contributors**

Concept and study design: MBi, AS, CJB, MW, JS, IHW, SK, AL, HBZ; Patient recruitment, data collection: KK, MBi, DH, PS, MT, MBI, JA, AD, UMR, ABo; Translational study design, molecular studies, data collection, data analysis, data interpretation: ABr, CS, LP, KK, CW, MBa, AH, MBi, MW, ABe, IHW; Statistical analysis: AH, LP; Drafting of the manuscript: ABr, MBi, CS. Critical revision of the manuscript for important intellectual content: all authors. All authors agreed to submit the manuscript and read and approved its content.

397

398 Acknowledgements

We thank all patients and families as well as all participating study centers.

401 References

1. M. Gormley, G. Creaney, A. Schache, K. Ingarfield, D. I. Conway, Reviewing the 402 403 epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J 404 233, 780-786 (2022). 405 2. D. E. Johnson et al., Head and neck squamous cell carcinoma. Nat Rev Dis Primers 406 6, 92 (2020). 3. L. Q. M. Chow, Head and Neck Cancer. N Engl J Med 382, 60-72 (2020). 407 A. Lau, W. F. Yang, K. Y. Li, Y. X. Su, Systemic Therapy in Recurrent or Metastatic 408 4. Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-409 Analysis. Crit Rev Oncol Hematol 153, 102984 (2020). 410 5. J. B. Vermorken et al., Platinum-based chemotherapy plus cetuximab in head and 411 neck cancer. N Engl J Med 359, 1116-1127 (2008). 412 6. B. Burtness et al., Pembrolizumab alone or with chemotherapy versus cetuximab 413 414 with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 415 1915-1928 (2019). 416 417 7. B. Burtness et al., Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: 418 419 Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin 420 Oncol 40, 2321-2332 (2022). 421 8. E. B. Ellingsen et al., Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three 422 phase I clinical trials. J Immunother Cancer 10, (2022). 423 S. Beyaert, J. P. Machiels, S. Schmitz, Vaccine-Based Immunotherapy for Head and 424 9. 425 Neck Cancers. Cancers (Basel) 13, (2021). 10. C. B. Harley, Telomerase and cancer therapeutics. Nat Rev Cancer 8, 167-179 426 (2008). 427

428 11. A. N. Guterres, J. Villanueva, Targeting telomerase for cancer therapy. *Oncogene*429 **39**, 5811-5824 (2020).

- N. W. Kim *et al.*, Specific association of human telomerase activity with immortal cells
 and cancer. *Science* 266, 2011-2015 (1994).
- A. Brandt, B. Thiele, C. Schultheiß, E. Daetwyler, M. Binder, Circulating Tumor DNA
 in Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)* 15, (2023).
- A. Brandt *et al.*, Tolerability and efficacy of the cancer vaccine UV1 in patients with
 recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma
 planned for first-line treatment with pembrolizumab the randomized phase 2
 FOCUS trial. *Front Oncol* 14, 1283266 (2024).
- J. Guigay *et al.*, Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil,
 and cetuximab as first-line treatment in patients with recurrent or metastatic head and
 neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, openlabel, randomised, phase 2 trial. *Lancet Oncol* 22, 463-475 (2021).
- 442 16. J. Guigay *et al.*, Cetuximab versus methotrexate in first-line treatment of older, frail
 443 patients with inoperable recurrent or metastatic head and neck cancer (ELAN
 444 UNFIT): a randomised, open-label, phase 3 trial. *Lancet Healthy Longev* 5, e182445 e193 (2024).
- 446 17. D. F. Eytan, A. L. Blackford, D. W. Eisele, C. Fakhry, Prevalence of Comorbidities
 447 among Older Head and Neck Cancer Survivors in the United States. *Otolaryngol*448 *Head Neck Surg* 160, 85-92 (2019).

V. D. Haakensen *et al.*, UV1 telomerase vaccine with ipilimumab and nivolumab as
second line treatment for pleural mesothelioma - A phase II randomised trial. *Eur J Cancer* 202, 113973 (2024).

452 19. K. J. Harrington *et al.*, Pembrolizumab With or Without Chemotherapy in Recurrent or
453 Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase
454 III KEYNOTE-048 Study. *J Clin Oncol* **41**, 790-802 (2023).

455	20.	L. L. Matos, L. P. Kowalski, The need to include older patients with head and neck
456		cancer in clinical trials. Lancet Healthy Longev 5, e380-e381 (2024).
457 458	21.	R. P. A'Hern, Sample size tables for exact single-stage phase II designs. <i>Stat Med</i> 20 , 859-866 (2001).
459	22.	B. Seliger et al., Induction of pulmonary HLA-G expression by SARS-CoV-2 infection.
460		Cell Mol Life Sci 79 , 582 (2022).